Hans Gerhard Creutzfeldt

Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases

Retrieved on: 
Tuesday, September 13, 2022
Tauopathy, FFI, Risk, Superoxide dismutase, Inflammation, Variant Creutzfeldt–Jakob disease, Memory, Human, FTD, Twitter, NYSE, Brain, AD, Hans Gerhard Creutzfeldt, FSE, BSE, EUE, Neurodegeneration, Parkinson's disease, LinkedIn, Company, GSS, CWD, Cognition, Stroke, Bovine spongiform encephalopathy, CTE, Forward-looking statement, U.S. Securities and Exchange Commission, Prion, Patient, CEO, Creutzfeldt–Jakob disease, Huntington's disease, Chronic traumatic encephalopathy, Annual report, TDP43, Scrapie, Toxicity, ALS, Security (finance), Pharmacokinetics, Chronic wasting disease, Frontotemporal dementia, PD, Gian Maria Annovi, TME, Patent, Axonal transport, Alzheimer's disease, CJD, Pharmaceutical industry, Vaccine, Huntingtin

The patents cover methods of treating amyloid lateral sclerosis (ALS), Huntington's disease, and prion diseases by administering buntanetap.

Key Points: 
  • The patents cover methods of treating amyloid lateral sclerosis (ALS), Huntington's disease, and prion diseases by administering buntanetap.
  • A method of treating amyloid lateral sclerosis, a rare progressive neurodegenerative disorder, by administering buntanetap and inhibiting the synthesis of superoxide dismutase protein1 and TDP43.
  • A method of treating Huntington's disease, a rare progressive neurodegenerative disorder, by administering buntanetap and inhibiting the synthesis of Huntingtin protein.
  • For more information on Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and Twitter .

Blood Emergency: Vitalant Supply Falls by Nearly 50%

Retrieved on: 
Monday, August 22, 2022
Creutzfeldt–Jakob disease, View, Blood, Food, Criticism of the Food and Drug Administration, Hans Gerhard Creutzfeldt, Hospital, Multimedia, Labour, Instagram, Plasma, Emergency, FDA, Twitter, United Kingdom, Risk, Science, Patient, Medical device, Online shopping, Vitalant, Facebook

SCOTTSDALE, Ariz., Aug. 22, 2022 /PRNewswire/ -- Continued strong patient needs for blood have depleted Vitalant's supply by nearly 50% since the start of summer, creating an emergency shortage across the country.

Key Points: 
  • "Hospitals need people to donate during these critical weeks," said Vitalant Chief Medical and Scientific Officer Dr. Ralph Vassallo.
  • Several patients may experience emergencies, while a planned surgery could suddenly require dozens of units of blood for one patient.
  • Appointments for all blood types are needed to achieve a sufficient four-day supply of all blood types.
  • Vitalant ("Vye-TAL-ent") is the nation's largest independent, nonprofit blood services provider exclusively focused on providing lifesaving blood and comprehensive transfusion medicine services for about 900 hospitals and their patients across the U.S. Every day, Vitalant needs to collect nearly 5,000 blood, platelet and plasma donations to help save lives.

Kedrion Biopharma to commercialize RYPLAZIM® (plasminogen, human-tvmh) in U.S. to address unmet need in patients with ultra-rare condition: Plasminogen Deficiency Type 1

Retrieved on: 
Wednesday, October 20, 2021
Virus, Mouth, Security (finance), Ligneous conjunctivitis, Human, Fatigue, Patient, Bleeding, Hypersensitivity, Immune system, Risk, Anticoagulant, Visual impairment, Private Securities Litigation Reform Act, Xerostomia, Collection, Gamma globulin, Headache, Macrocytic anemia, Fibrin, Abdominal pain, Acquisition, Anti-tetanus immunoglobulin, Nausea, U.S. Securities and Exchange Commission, VTE, Dizziness, FDA, Constipation, Hans Gerhard Creutzfeldt, Forward-looking statement, Plasma, Arthralgia, Pathogen, Back pain, Castelvecchio Pascoli, Anaphylaxis, Shortness of breath, Sumathi Best Television Current Reporting Award, CJD, Bloating, Degenerative disease, Goal, Thrombosis, Fetus, Research, Creutzfeldt–Jakob disease, Infection, Paroxysmal extreme pain disorder, Plasmin, Pharmaceutical industry, Medical device, Vaccine

"The most important mission at Kedrion Biopharma is to improve the lives of people with rare and serious diseases," said Kedrion Biopharma Chief Executive Officer, Val Romberg.

Key Points: 
  • "The most important mission at Kedrion Biopharma is to improve the lives of people with rare and serious diseases," said Kedrion Biopharma Chief Executive Officer, Val Romberg.
  • RYPLAZIM meets an urgent unmet medical need for people who face plasminogen deficiency type 1, a potentially devastating, but treatable, medical condition.
  • The Prometic deal also brings more cutting-edge purification technology to the Kedrion Biopharma group.
  • Kedrion Biopharma is ramping up RYPLAZIM production capacity to meet patient demand and anticipates RYPLAZIM will be available in limited quantities in 2022.

U.S. FDA Approves TICOVAC™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine

Retrieved on: 
Saturday, August 14, 2021
Biotechnology, FDA, Infectious Diseases, Health, Pharmaceutical, Blood, European Centre for Disease Prevention and Control, Clinical trial, Water, Research, Muscle weakness, Control, Degenerative disease, Inc., Elsevier, Safety, Vaccine, PFE, Human, CJD, LinkedIn, Allergy, Risk, FDA, Vaccination, Tick-borne encephalitis, Facebook, News, Hans Gerhard Creutzfeldt, Regulation of tobacco by the U.S. Food and Drug Administration, Adult, Fever, NYSE, Creutzfeldt–Jakob disease, Science, COVID-19, U.S. Securities and Exchange Commission, Fatigue, Tick, Profile, Anaphylaxis, CDC, TBE, Restless, Doctor of Philosophy, ACIP, YouTube, Brain, Twitter, Review, ECDC, Health, Headache, R, IJMM, Pharmaceutical industry, Animal

This vaccine has helped to protect millions of people in TBE endemic regions since its first approval outside the U.S. 45 years ago.

Key Points: 
  • This vaccine has helped to protect millions of people in TBE endemic regions since its first approval outside the U.S. 45 years ago.
  • A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans.
  • Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies.
  • Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity.